MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development

Shaowei Li, Fumiko Takeuchi, Ji-an Wang, Christopher Fuller, Gustavo Pacheco-Rodriguez, Joel Moss, and Thomas N. Darling

1Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814
2Pulmonary-Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892

Patients with tuberous sclerosis complex (TSC) develop hamartomatous tumors showing loss of function of the tumor suppressor TSC1 (hamartin) or TSC2 (tuberin) and increased angiogenesis, fibrosis, and abundant mononuclear phagocytes. To identify soluble factors with potential roles in TSC tumorigenesis, we screened TSC skin tumor–derived cells for altered gene and protein expression. Fibroblast-like cells from 10 angiofibromas and five periungual fibromas produced higher levels of monocyte chemoattractant protein-1 (MCP-1) mRNA and protein than did fibroblasts from the same patient’s normal skin. Conditioned medium from angiofibroblast cells stimulated chemotaxis of a human monocytic cell line to a greater extent than conditioned medium from TSC fibroblasts, an effect blocked by neutralizing MCP-1–specific antibody. Overexpression of MCP-1 seems to be caused by loss of tuberin function because Eker rat embryonic fibroblasts null for Tsc2 (EEF Tsc2−/−) produced 28 times as much MCP-1 protein as did EEF Tsc2+/+ cells; transient expression of WT but not mutant human TSC2 by EEF Tsc2−/− cells inhibited MCP-1 production; and pharmacological inhibition of the Rheb-mTOR pathway, which is hyperactivated after loss of TSC2, decreased MCP-1 production by EEF Tsc2−/− cells. Together these findings suggest that MCP-1 is an important paracrine factor for TSC tumorigenesis and may be a new therapeutic target.

Patients with tuberous sclerosis complex (TSC) are predisposed to developing tumors in the brain, eyes, heart, kidneys, lung, and skin. Although typically benign, these tumors cause significant morbidity, including seizures, mental retardation, and disfigurement. The tendency to form multiple tumors is a consequence of inactivating mutations in a tumor-suppressor gene, either TSC1 or TSC2 (1). The products of these genes, hamartin and tuberin, seem to function as a complex to regulate many cellular processes, in particular signaling through the PI3K-Akt-TSC1/2-Rheb-mTOR pathway (2). Loss of function of the hamartin–tuberin complex in TSC tumors enhances mTOR signaling leading to increased cell numbers and cell size.

Skin tumors, including multiple facial angiofibromas and periungual fibromas, are observed in ~90% of patients with TSC (3). Histologically, angiofibromas and periungual fibromas show increased vessels and fibrosis. There are also increased numbers of cells in the interstitial dermis, predominantly spindle-shaped, fibroblast-like cells together with stellate cells that seem to be monocyte-derived DCs, based on immunoreactivity for factor XIIIa (4–6). These features are shared variably by TSC tumors in other organs. Increased angiogenesis is observed in TSC–associated tumors of the kidney, lung, and brain (7), and increased numbers of cells positive for factor XIIIa have been observed in subependymal giant cell astrocytomas and angiomyolipomas (4). More recently, tubers have been reported to contain increased numbers of cells expressing CD68, a marker used to identify cells of the monocyte/macrophage/DC lineage (8). It has not been determined what induces the mixture of cell populations composing these hamartomatous tumors and whether this cellular heterogeneity is related to loss of hamartin–tuberin function.

The mixed cellular composition of TSC tumors points to a role for soluble growth factors in their development. Prompted by the increased vascularity of TSC tumors, others have investigated angiogenic factors. TSC tumors of the
skin, brain, and kidney produce vascular endothelial growth factor (VEGF) (7, 9, 10). Furthermore, overexpression of VEGF is related to loss of tuberin function and is at least partially mTOR-dependent (11, 12). It has been proposed that overexpression of VEGF is a unifying feature of hamartoma syndromes (13).

To identify soluble growth factors involved in the development of TSC skin tumors, we profiled cytokine mRNA levels and protein production in cultured angiofibroma and periungual fibroma cells. TSC skin tumor cells overexpressed MCP-1, a chemokine that stimulates angiogenesis, fibrosis, and recruitment of monocytes. The relationship between MCP-1 production and loss of tuberin function was investigated using EEF Tsc2−/− cells and pharmacological inhibitors of the PI3K-Akt-mTOR pathway. These experiments indicate that overexpression of MCP-1 in EEF Tsc2−/− cells is mTOR-dependent and is related to loss of tuberin function.

RESULTS

Angiofibromas and periungual fibromas show increased vessels, fibrosis, and mononuclear phagocytes

Angiofibromas and periungual fibromas contained greater numbers of dermal cells positive for CD68 than did patient’s normal-appearing skin (Fig. 1). These positive cells were stellate or polygonal in shape. As previously reported for angiofibromas (4–6), more cells positive for factor XIIIa, another marker for monocyte-derived cells, were seen in angiofibromas and periungual fibromas than in normal-appearing skin (unpublished data). As expected, angiofibromas and periungual fibromas had greater numbers of endothelial cells positive for CD34 and dermal cells positive for vimentin than did normal-appearing skin (unpublished data). There were sparse but elevated numbers of cells positive for S100 in the papillary dermis, and there were almost no cells in the dermis positive for HMB-45 (unpublished data). The intensity of staining for smooth muscle actin was greater in perivascular cells of angiobromas and periungual fibromas than in normal-appearing skin (unpublished data). Thus, increased cellularity in these skin tumors derives from several cell lineages.

Cells cultured from angiofibromas and periungual fibromas express fibroblast markers

We hypothesized that the abnormal cellular composition of TSC skin tumors was related to altered expression of soluble growth factors. To generate an in vitro system for study, cells were grown from angiofibromas, periungual fibromas, and the patient’s normal-appearing skin using standard methods for culturing fibroblasts. Cells grown from angiofibromas and periungual fibromas were bipolar or multipolar, as previously reported (14, 15). Immunocytochemistry was used to distinguish cells from different lineages, using, for example, an antibody to the collagen chaperone HSP47 to detect fibroblasts (16). Fibroblasts from normal-appearing skin of a TSC patient (hereafter referred to as TSC fibroblasts) and angiofibroma cells from the same patient expressed HSP47 but not CD68 (Fig. 2, A–F). They also expressed vimentin but not CD14, S100, or smooth muscle actin (unpublished data).

Angiofibroma and periungual fibroma cells show altered expression of soluble growth factors

A cytokine cDNA array was used to compare gene expression, using total RNA from paired cultures of TSC fibroblasts and angiofibroma cells from three patients. In the studies reported below, cells were incubated in DMEM plus 1% FBS for 1 d to reduce extrinsic stimulation of cytokine production, unless noted otherwise. Four of 268 genes were overexpressed by a mean of threefold or more, including MCP-1 (9.8-fold), insulin-like growth factor-binding protein 2 (IGFBP2) (8.1-fold), secreted frizzled-related protein 2 (3.2-fold), and IGFBP5 (3.0-fold). For VEGF, the mean ratio of tumor to TSC fibroblasts was 1.4. It is interesting that IGFBP3 expression was reported in an earlier study of angiofibroma cells (17), and that IGFBP1, IGFBP2, IGFBP4, IGFBP5, and IGFBP6 are expressed in pulmonary lesions of lymphangioleiomyomatosis, that also exhibit mutations in TSC genes (18).

Because changes in mRNA expression are not always reflected at the protein level, the levels of MCP-1 and 10
Levels of MCP-1 mRNA in angiofibroma cells and periungual fibroma cells were 1.3- to 33-fold (n = 10, P = 0.001) and 1.8- to 4.9-fold (n = 5, P = 0.007), respectively, greater than those in TSC fibroblasts (Table I). MCP-1 protein was measured using ELISA, and results were normalized to total cellular ATP levels after demonstrating the same linear relationship of cell number and cellular ATP in TSC fibroblasts and angiofibroma cells (unpublished data). Almost all of the MCP-1 produced was released into the medium, with only 5% recovered in cell lysates (unpublished data). TSC angiofibroma cells and periungual fibroma cells released 1.4- to 104-fold (P < 0.001) and 1.4- to 4.1-fold (P < 0.015), respectively, as much MCP-1 into the medium as TSC fibroblasts (Table I). The fold changes in MCP-1 mRNA correlated with those of MCP-1 protein (n = 15; Pearson correlation = 0.868; P < 0.001). Serum stimulated MCP-1 production by both TSC fibroblasts and angiofibroma cells (P < 0.001), but the effect was greater in angiofibroma cells (P < 0.001; Fig. 4).

To test biological activities of MCP-1 produced by TSC tumor cells, we performed proliferation and chemotaxis assays. Proliferation of normal human fibroblasts, TSC fibroblasts, and angiofibroma cells was measured using a proliferation assay. MCP-1 protein was measured using ELISA, and results were normalized to total cellular ATP levels after demonstrating the same linear relationship of cell number and cellular ATP in TSC fibroblasts and angiofibroma cells (unpublished data). Almost all of the MCP-1 produced was released into the medium, with only 5% recovered in cell lysates (unpublished data). TSC angiofibroma cells and periungual fibroma cells released 1.4- to 104-fold (P < 0.001) and 1.4- to 4.1-fold (P < 0.015), respectively, as much MCP-1 into the medium as TSC fibroblasts (Table I). The fold changes in MCP-1 mRNA correlated with those of MCP-1 protein (n = 15; Pearson correlation = 0.868; P < 0.001). Serum stimulated MCP-1 production by both TSC fibroblasts and angiofibroma cells (P < 0.001), but the effect was greater in angiofibroma cells (P < 0.001; Fig. 4).

Table I. Cells derived from angiofibromas and periungual fibromas express higher levels of MCP-1 mRNA and protein than do fibroblasts from the same patient

| Patient | Tumor | mRNA<sup>a</sup> | Protein<sup>b</sup> |
|---------|-------|-----------------|-----------------|
| 1       | AF    | 33              | 15              |
|         | PF    | 2.1             | 1.7             |
| 2       | AF    | 12              | 19              |
| 3       | AF    | 6.4             | 6.0             |
| 4       | AF    | 1.3             | 1.4             |
|         | PF    | 2.0             | 1.4             |
| 5       | AF    | 4.5             | 1.9             |
|         | PF    | 2.9             | 2.0             |
| 6       | PF    | 4.9             | 4.1             |
| 7       | AF1   | 1.6             | 3.9             |
| 8       | AF    | 20              | 32              |
| 9       | AF    | 2.9             | 3.5             |
|         | PF    | 1.8             | 3.2             |
| 10      | AF    | 5.2             | 15              |

<sup>a</sup>Real-time PCR was used to measure MCP-1 mRNA levels in triplicate. Results were normalized to 18S rRNA, and results were expressed as a ratio of angiofibroma or periungual fibroma to TSC fibroblasts.

<sup>b</sup>An ELISA was used to measure MCP-1 in culture supernatants in triplicate. Results were normalized by total cellular protein and expressed as a ratio of tumor to normal.

<sup>c</sup>Equal numbers of cells were incubated for 24 h in DMEM plus 1% FBS. AF, angiofibroma; PF, periungual fibroma.
blasts, and angiofibroma cells was similar whether growing in conditioned medium from angiofibroma cells (containing 740 pg/ml MCP-1) or from TSC fibroblasts (containing 44 pg/ml MCP-1; unpublished data). Likewise, recombinant MCP-1 (1,000 pg/ml) had no significant effect on proliferation of these cells (unpublished data). Thus, MCP-1 did not seem to be a major mitogen for angiofibroma cells, but MCP-1 produced by angiofibroma cells did stimulate chemotaxis of THP-1 cells, a human monocytic cell line. THP-1 cell migration in response to conditioned medium from angiofibroma cells was greater than migration in response to medium from TSC fibroblasts alone (P < 0.019) or plus control IgG (P = 0.007), whereas the addition of neutralizing antibody to MCP-1 abrogated the effect on migration (Fig. 5). Findings were similar using recombinant MCP-1 (5 ng/ml) as a positive control: IgG had no effect, and anti-MCP-1 antibody blocked chemotactic activity (unpublished data). Thus, MCP-1 produced by angiofibroma cells may play a significant role as a chemotactic factor, recruiting cells into the tumor.

Overexpression of MCP-1 by tuberin-null rat fibroblasts is inhibited by TSC2 transfection or inhibition of mTOR signaling

To investigate the relationship between MCP-1 production and tuberin function in a homogeneous, genetically defined cell population, we compared EEF Tsc2−/− cells with those expressing tuberin (EEF Tsc2+/+). EEF Tsc2−/− cells produced significantly more MCP-1 than did EEF Tsc2+/+ cells (P < 0.01 at all times tested; Fig. 6). To evaluate further whether loss of tuberin leads to increased MCP-1 production, we transiently transfected EEF Tsc2−/− cells with full-length human TSC2 cDNA constructs including one WT, two human polymorphisms, and two mutants identified in TSC patients (19). Under conditions that yielded a transfection efficiency of 50% for GFP (unpublished data), transfection with WT tuberin or two nonpathogenic missense polymorphisms (M286V and R367Q) decreased MCP-1 production by ~50% (P = 0.005; Fig. 7). A dose-response for transfection with WT tuberin showed that tuberin significantly inhibited MCP-1 production in a dose-dependent manner (Fig. 7). In contrast, two nontruncating mutants (G294E and I365del) known to disrupt binding of tuberin to hamartin (19) had no effect on MCP-1 production (Fig. 7). Because tuberin negatively regulates signaling through the PI3K-Akt-TSC1/2-
Rheb-mTOR pathway, we tested the effects of pharmacological inhibition of this pathway on MCP-1 production by EEF Tsc2/−/− cells. The inhibitors used were rapamycin, a specific inhibitor of mTOR, FTI-277, a farnesyl transferase inhibitor that blocks production of active Rheb, and LY294002, a PI3K and mTOR inhibitor. Each of these compounds significantly suppressed MCP-1 production in a concentration-dependent manner (*, P < 0.01; Fig. 8). None of the compounds was cytotoxic at the concentrations tested (unpublished data). Thus, overexpression of MCP-1 by EEF Tsc2/−/− cells was mTOR-dependent.

**DISCUSSION**

The cellular composition of TSC tumors is mixed, implicating paracrine factors in their development. Previous studies have focused on the increased vessels in TSC tumors and have shown increased expression of VEGF (7, 9–12). We found that TSC skin tumors, in addition to having more blood vessels and fibrosis than normal skin, show greater numbers of CD68-positive cells, and that cells derived from TSC skin tumors overexpress MCP-1, a chemokine with roles in angiogenesis, fibrosis, and recruitment of monocytes. We also showed that conditioned medium from cultured TSC skin tumor cells was chemotactic for human monocytic cells, and neutralizing antibody against MCP-1 inhibited the chemotactic activity. These data suggest that MCP-1 is a paracrine factor that contributes to TSC tumorigenesis.

MCP-1 and its receptor, CCR2, are expressed by a variety of cells including skin fibroblasts, and are up-regulated in a variety of pathological processes (20, 21). MCP-1 expression has been associated with tumor vascularity (22) and is critical for hemangioendothelioma proliferation (23). MCP-1 can stimulate angiogenesis directly (24) and indirectly through recruitment of monocytes (25). MCP-1 is overexpressed in fibrotic processes and has a variety of fibrogenic effects (21, 26, 27). Thus, it is likely that MCP-1 overexpression in TSC skin tumors stimulates angiogenesis and fibrosis.

MCP-1 is chemotactic for monocytes and for peripheral blood myeloid DCs (28). Expression of MCP-1 is associated with the appearance of tumor-associated macrophages (29) and with recruitment of DCs into skin (30). It has been proposed that mononuclear phagocytes both stimulate tumor formation through effects on angiogenesis and release of mitogens and, in other systems, inhibit tumor growth through immunologic effects (29). In TSC skin tumors, the balance of growth-promoting and growth-inhibitory effects of tumor-associated mononuclear phagocytes may lead to the long-term stable size of cutaneous tumors. Disruption of this balance may represent a new therapeutic approach for these tumors.

TSC skin tumors are heterogeneous in cell lineages and genetically. Although it has been possible to show loss of heterozygosity (LOH) at the TSC2 locus in other TSC tumors, angiofibromas and periungual fibromas often do not show LOH (31), probably because of the mixture of
TSC2\(^{+/−}\) cells and TSC2\(^{−/−}\) cells in such lesions. Immunohistochemical studies of hamartin and tuberin expression are consistent with this interpretation. When loss of hamartin and tuberin expression is observed in angiofibromas, the cells showing decreased staining are the interstitial cells, not endothelial cells (32). We have not detected LOH in our cultured angiofibroma cells or periangi tumoral fibroblasts, in agreement with the results of others (33). However, most of these cultures show allelic deletion of the TSC2 gene in a minority of the cells (34). In addition, angiofibroma cells and periangi tumoral fibroblasts exhibit hyperphosphorylation of ribosomal protein S6 under conditions of serum starvation (35), which is also observed in other TSC-related tumors as a consequence of loss of tuberin function and activation of mTOR signaling. Together, these observations suggest that increased MCP-1 production by these angiofibroma cells and periangi tumoral cells is related to defective tuberin function, although the possibility of additional genetic or epigenetic alterations cannot be excluded.

To explore the relationship of defective tuberin function and MCP-1 production and MCP-1 production, we used EEF Tsc2\(^{−/−}\) cells. Much more MCP-1 was produced by EEF Tsc2\(^{−/−}\) cells than by EEF Tsc2\(^{+/−}\) cells. MCP-1 production by EEF Tsc2\(^{−/−}\) cells was reduced by transient transfection with human tuberin and was suppressed by rapamycin, a specific inhibitor of mTOR. These results indicate that MCP-1 overexpression by EEF Tsc2\(^{−/−}\) cells is caused by defective tuberin function and dysregulated mTOR-dependent signaling. Recently, it was shown that transgenic mice overexpressing a dominant-negative allele of tuberin develop fibrovascular collagenomas in the skin, and that these skin lesions show increased expression of MCP-1 as compared with WT skin (36). Others have found that rapamycin inhibits MCP-1 production in animal models of atherosclerosis (37) and transplant rejection (38, 39). It is interesting that loss of tuberin function and increased activation of the Rheb/mTOR/S6K pathway induce insulin receptor substrate-1 depletion and insulin resistance (40, 41), and that baseline levels of MCP-1 are increased in insulin-resistant 3T3-L1 adipocytes and in insulin-resistant obese mice (42).

In conclusion, MCP-1 is overexpressed by TSC skin tumor cells and probably exerts paracrine effects leading to angiogenesis, fibrosis, and recruitment of monocytes. Blocking MCP-1 has been effective for treatment of a variety of conditions in experimental animals, including atherosclerosis (43), pulmonary fibrosis (27), and renal fibrosis (26), and antibodies to MCP-1 has been effective for treatment of a variety of conditions in experimental animals, including atherosclerosis (43), pulmonary fibrosis (27), and renal fibrosis (26), and antibodies to MCP-1 have been used in animal models of pulmonary fibrosis (28), renal fibrosis (29), and atherosclerosis (30). MCP-1 is also a therapeutic target for TSC skin tumors in humans.

MATERIALS AND METHODS

Tumor samples and cell culture. Adult patients, diagnosed with TSC according to clinical criteria (45) were enrolled after institutional review board approval (National Heart, Lung, and Blood Institute Institutional Review Board–approved protocol 00-H-0051). Cells cultured from explants of angiofibromas, periangi tumoral fibroblasts, and patients’ normal-appearing skin as previously described (14), from normal adult human fibroblasts (Cambrex Bio Science), and from EEF Tsc2\(^{−/−}\) and EEF Tsc2\(^{+/−}\) cells (46) were grown in DMEM supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100 µg/ml). Human monocyte cell lines U937 and THP-1 (ATCC), were grown in RPMI 1640 medium with 10% FBS.

Immunohistochemical and immunocytochemical staining. 6-µm sections of four angiofibromas, four periangi tumoral fibromas, and four samples of normal-appearing skin from six patients were immunostained using the autostainer (DakoCytomation) according to the manufacturer’s recommendations with antibodies against S100 (1:600), HMB-45 (1:50), smooth muscle actin (1:200), CD34 (1:75), CD68 (1:200, vimentin (1:200) (DakoCytomation) and factor XIIIa (BioGenex). An avidin-biotin peroxidase detector kit (DakoCytomation) was used with diaminobenzidine as the chromogen and Gill’s hematoxylin as the counterstain.

TSC fibroblasts, angiofibroma cells, or human monocyte cells (5 × 10⁴ cells per chamber) on four-chamber slides (Nalge Nunc International) were incubated overnight in DMEM plus 10% FBS, followed by DMEM plus 1% FBS for 24 h. After fixation, permeabilization, and blocking, cells were incubated with mouse anti–Hsp47 monoclonal antibody (3 µg/ml; StressGen Biotechnologies), anti–CD68 monoclonal antibody (1:100 dilution; DakoCytomation), Texas red α-smooth muscle actin (1:100; Sigma–Aldrich), or HMB45 (1:25; DakoCytomation) overnight at 4°C, and then with Alexa Fluor 488 goat anti–mouse IgG (1:1,000; Molecular Probes) at room temp for 1 h before nuclei were stained with DAPI.

Gene expression arrays. Early-passage human cells (P = 3–5) were incubated over night in DMEM plus 1% FBS 24 h before harvesting. Total RNA was extracted from primary cultured cells using a phenol-based kit (TRIZol, GibCO BRL), followed by further purification using an RNAsafe Midi-Column (QIAGEN) and concentration using Microcon YM-30 (Millipore). Radiolabeled cDNA probes, made using a gene-specific primer mix and [³²P]dATP, were hybridized to the Clontech Atlas Human Cytokine/Receptor Array (BD Biosciences), according to manufacturer’s instructions. To quantify signal intensity, a phosphorimager (Storm 860, Molecular Dynamics, Inc.) was used at a pixel resolution of 100 µm. These data were analyzed using P-SCAN (peak quantification using statistical comparative analysis) software, version 1.2 and MATLAB 6.1 (The MathWorks, Inc.).

Culture supernatant cytokine array. Human cells (5 × 10⁴ cells/well) were incubated overnight on six-well plates in 10% FBS/DMEM. The medium was switched to 1% FBS/DMEM, and the cells were incubated for 24 h. The levels of 11 cytokines (MCP-1, VEGF, platelet-derived growth factor-bb, TNFα, fibroblast growth factor, IL-7, IL-8, GM-CSF, lymphotakin, IFN-γ, insulin-like growth factor 1, and leukemia inhibitory factor) were measured in supernatants using a multiplexed ELISA (SearchLight Array).

Human MCP-1 mRNA and protein. Human cells (1 × 10⁶ cells/plate) were grown overnight on 10-cm plates in 10% FBS/DMEM, then were switched to 1% BSA/DMEM and the incubation was continued for 24 h. Supernatants were collected, and total RNA was extracted from the cells using the RNeasy Mini Kit (QIAGEN). MCP-1 mRNA and 18S rRNA were measured using RT PCR with MCP-1 or 18S rRNA primers and FAM dye-labeled probe (MCP-1, 18S rRNA; Assays-on-Demand, Applied Biosystems) on an ABI PRISM 7500 Sequence Detection System Instrument (Applied Biosystems). MCP-1 was measured in supernatants using an ELISA specific for human MCP-1 (R&D Systems). Cellular lysates were prepared in 10 mM Tris buffer, pH 7.4, 100 mM NaCl, 1% Triton X-100, 10% glycerol, 0.1% SDS, 1 mM PMSF and a mixture of protease inhibitors (Sigma–Aldrich). Total cellular protein was measured using BCA reagent (Pierce Chemical Co.).

Proliferation and chemotaxis assays. Cells (1,500 cells/well in 96-well plates) were incubated overnight in 10% FBS/DMEM, before the medium was changed to 1% BSA/DMEM (no serum) with or without MCP-1 (1 ng/ml) (Pepro Tech) or 2% FBS/DMEM. Cells were incubated for 72 h,
with medium changed every 24 h. Cell number was assessed by measuring cellular ATP content with a luminescence assay (ATPlite, PerkinElmer) and BMG FLUOstar plate reader (BMG Lab Technologies). For preparation of conditioned medium, TSC fibroblasts or angiofibroma cells in 10-cm dishes (1 × 10⁶ cells/dish) were incubated overnight in 10% FBS/DMEM before the medium was replaced with 1% FBS/DMEM and incubation continued for an additional 24 h. Culture supernatants were then collected and stored at −70°C.

Monocyte chemotaxis was assayed using Chemicon QCM 96-well cell migration assay (8-μm pore size) (CHEMICON International, Inc.). THP-1 cells were incubated in 1% FBS/DMEM for 24 h before transferring 1.5 × 10⁴ cells/100 μl of the same medium to migration chambers. Conditioned medium (150 μl/well) was added to the feeder tray. Recombinant human MCP-1 was used as the positive control. In neutralization studies, the conditioned medium was incubated with 10 μg/ml of either anti-human MCP-1 monoclonal antibody (R&D Systems) or control mouse IgG (R&D Systems) for 2 h at 4°C before use in chemotaxis assays.

**Rat MCP-1.** Rat embryonic fibroblasts (5 × 10⁵ cells/well) were grown overnight on six-well plates in 10% FBS/DMEM before switching to 2% FBS/DMEM, and incubation continued for the indicated time. Rat MCP-1 was measured in culture medium by ELISA (Pierce Chemical Co.).

**Gene transfection.** Rat EEF Tsc2+/− cells were transfected with WT TSC2, mutant TSC2, or TSC2 polymorphism in pCMVTag2 (J. Sampson, Cardiff, UK) or with the empty vector by nucleofection technology using MEF Nucleofector kits (Amaza Biosystems) according to the manufacturer’s instructions. After transfection, cells were maintained in DMEM with 10% FBS overnight before the culture medium was replaced with DMEM containing 2% FBS, and incubation continued for an additional 24 h. Culture supernatants were collected for assay of MCP-1 by ELISA. Cells were lysed, and cell lysates were subjected to SDS-PAGE and immunoblotting for tuberin using rabbit anti-tuberin C-20 (Santa Cruz Biotechnology, Inc.) and monoclonal anti-β-actin antibody AC-15 (Sigma-Aldrich).

**Cell treatment.** Rat embryonic fibroblasts plated in 12-well plates (2 × 10⁵ cells/well) were incubated in 10% FBS/DMEM overnight before incubation for 4 h with serum-free DMEM containing indicated concentrations of rapamycin (EMD Biosciences, Inc.), FTI-277 (EMD Biosciences, Inc.), or LY29402 (BIOMOL Research Laboratories, Inc.), followed by an additional 24 h in fresh medium with the same inhibitor. Cell culture supernatants were collected, and MCP-1 was quantified by ELISA. The concentrations of total secreted proteins in cell culture supernatants were quantitated by Bio-Rad Protein Assay (Bio-Rad Laboratories). Cell death was measured by lactate dehydrogenase release with the CytoTox96 Non-Radioactive Cytotoxicity Assay (Promega) according to the manufacturer’s instructions.

**Statistics.** Cytokine ELISA data were analyzed using Wilcoxon signed ranks test. MCP-1 mRNA and protein data were analyzed using a one-sample t test to compare the average log ratio of fold-changes to the hypothesized value of 0 (no difference). The effects of serum on MCP-1 production by fibroblasts and angiofibroma cells from individuals with TSC were assessed using univariate analysis of variance. Overall significance of the effects of transfections or pharmacological agents on MCP-1 production was evaluated using analysis of variance, followed by Dunnett t test to compare each treatment group to control. For all other comparisons, significance was determined using t test with equal variances not assumed. Significance was defined as P < 0.05.

We thank the Tuberous Sclerosis Alliance and The LAM Foundation for patient referral. We also thank C. Olsen for statistical assistance and Dr. M. Vaughan for critical review and discussion of the manuscript.

This work was supported by a Clinical Scientist Development Award from the Doris Duke Charitable Foundation, grant no. 1 R01 CA100907 [to T.N. Darling], and the Intramural Research Program of the National Institutes of Health, National Heart, Lung, and Blood Institute. The authors have no conflicting financial interests.

Submitted: 2 December 2004
Accepted: 13 July 2005

**REFERENCES**

1. Sampson, J.R. 2003. TSC1 and TSC2: genes that are mutated in the human genetic disorder tuberous sclerosis. *Biochim. Soc. Trans.* 31:592–596.
2. Li, Y., M.N. Corradetti, K. Inoki, and K.L. Guan. 2004. TSC2: filling the GAP in the mTOR signaling pathway. *Trends Biochem. Sci.* 29:32–38.
3. Webb, D.W., A. Clarke, A. Fryer, and J.P. Osborne. 1996. The cutaneous features of tuberous sclerosis: a population study. *Br. J. Dermatol.* 135:1–5.
4. Pennys, N.S., K.J. Smith, and A.J. Nemeth. 1991. Factor XIIa in the hamartomas of tuberous sclerosis. *J. Dermatol. Sci.* 2:50–54.
5. Nemeth, A.J., and N.S. Pennys. 1989. Factor XIIa is expressed by fibroblasts in fibrovascular tumors. *J. Cutan. Pathol.* 16:266–271.
6. Benjamin, D.R. 1996. Cellular composition of the angiofibromas in tuberous sclerosis. *Pediatr. Pathol. Lab. Med.* 16:893–899.
7. Arbisser, J.L., D. Brat, S. Hunter, J. D’Armentino, E.P. Henske, Z.K. Arbisser, X. Bai, G. Goldberg, C. Cohen, and S.W. Weiss. 2002. Tuberculous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. *J. Am. Acad. Dermatol.* 46:376–380.
8. Maldonado, M., M. Baybis, D. Newman, D.L. Kollon, W. Chen, G. McKhann II, D.H. Gutmann, and P.B. Crino. 2003. Expression of ICAM-1, TNF-alpha, NFκappaB, and MAP kinase in tubers of the tuberous sclerosis complex. *Neurol. Dis.* 14:279–290.
9. Liu, M.Y., L. Poellinger, and C.L. Walker. 2003. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. *Cancer Res.* 63:2675–2680.
10. Nguyen-Vu, P.A., I. Fackler, A. Rust, J.E. DeClue, C.A. Sander, M. Volkenhardt, M. Flage, R.S. Yeung, and R. Wienecke. 2001. Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis. *J. Cutan. Pathol.* 28:470–475.
11. Brugarolas, J.B., F. Vazquez, A. Reddy, W.R. Sellers, and W.G. Kaelin Jr. 2003. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. *Cancer Cell.* 4:147–158.
12. El-Hademite, N., V.Walker, H. Zhang, and D.J. Kwiatkowski. 2003. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. *Cancer Res.* 63:5173–5177.
13. Brugarolas, J., and W.G. Kaelin Jr. 2004. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. *Cancer Cell.* 6:7–10.
14. Kato, M., T. Katsumoto, K. Ohno, S. Kato, F. Herz, and K. Takeshita. 1992. Expression of glial fibrillary acidic protein (GFAP) by cultured angiofibroma stroma cells from patients with tuberous sclerosis. *Neuropathol. Appl. Neurobiol.* 18:559–565.
15. Onodera, K., Y. Ishibashi, M. Sasaki, and G. Kimura. 1989. Abnormal division and gene expression in cultured cells from a patient with tuberous sclerosis. *J. Dermatol.* 16:263–269.
16. Kuroda, K., and S. Tajima. 2004. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. *Cancer Cell.* 6:7–10.
17. Ishibashi, Y., R. Watanabe, and K. Onodera. 1993. Tuberous Sclerosis: Advances in Clinical and Genetic Research. *In Dermatology: Progress & Perspectives.* W.H.C. Burgdorf, and S.I. Katz, editors. The Parthenon Publishing Group, New York. 764–766.
18. Valencia, J.C., K. Matsui, C. Bondy, J. Zhou, A. Rasmussen, K. Cullen, Z.X. Yu, J. Moss, and V.J. Ferrans. 2001. Distribution and *Cancer Cell.* 31:241–246.
19. Ishibashi, Y., R. Watanabe, and K. Onodera. 1993. Tuberous Sclerosis: Advances in Clinical and Genetic Research. *In Dermatology: Progress & Perspectives.* W.H.C. Burgdorf, and S.I. Katz, editors. The Parthenon Publishing Group, New York. 764–766.
20. Yamamoto, T., and K. Nishioka. 2003. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. *J. Invest. Dermatol.* 121:510–516.
21. Yamamoto, T. 2003. Potential roles of CCL2/monocyte chemoattractant protein-1 in the pathogenesis of cutaneous sclerosis. Clin. Exp. Rheumatol. 21:369–375.

22. Ohita, M., Y. Kitada, S. Tanaka, M. Yoshihara, W. Yasui, N. Mukaida, K. Haruma, and K. Chayama. 2003. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int. J. Oncol. 22:773–778.

23. Gondillo, G.M., D. Onat, M. Stockinger, S. Roy, M. Atlay, M. Beck, and C.K. Sen. 2004. A key angiogenic role of monocyte chemoattractant protein-1 in hemangioendothelia proliferation. Am. J. Physiol. Cell Physiol. 287:C866–C873.

24. Salcedo, B., M.L. Ponce, H.A. Young, K. Wasserman, J.M. Ward, H.K. Kleiman, J.J. Oppenheim, and W.J. Murphy. 2000. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood. 96:940–948.

25. Yoshida, S., A. Yoshida, H. Matsui, T. Takada, and T. Ishibashi. 2003. Involvement of macrophage chemotactic protein-1 and interleukin-1beta during inflammatory but not basic fibroblast growth factor-dependent neovascularization in the mouse cornea. Lab. Invest. 83:927–938.

26. Wada, T., K. Furuzchi, N. Sakai, Y. Iwata, K. Kitagawa, Y. Ishida, T. Kondo, H. Hashimoto, Y. Ishiwata, N. Mukaida, et al. 2004. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J. Am. Soc. Nephrol. 15:940–948.

27. Inoshima, I., K. Kuvano, N. Hamada, N. Hagimoto, M. Yoshimi, T. Maeyama, A. Takeshita, S. Kitamoto, K. Egashira, and N. Hara. 2004. Anti-macrophage chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 286: L1038–L1044.

28. de la Rosa, G., N. Longo, J.L. Rodriguez-Fernandez, A. Puig-Kroger, A. Pineda, A.L. Corbi, and P. Sanchez-Mateos. 2003. Migration of L1038–L1044.

29. Yoshida, S., A. Yoshida, H. Matsui, T. Takada, and T. Ishibashi. 2003. Involvement of macrophage chemotactic protein-1 and interleukin-1beta during inflammatory but not basic fibroblast growth factor-dependent neovascularization in the mouse cornea. Lab. Invest. 83:927–938.

30. Wada, T., K. Furuzchi, N. Sakai, Y. Iwata, K. Kitagawa, Y. Ishida, T. Kondo, H. Hashimoto, Y. Ishiwata, N. Mukaida, et al. 2004. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J. Am. Soc. Nephrol. 15:940–948.

31. Niida, Y., A.O. Stemmer-Rachamimov, M. Logrip, A.L. Corbi, and P. Sanchez-Mateos. 2003. Migration of human blood dendritic cells across endothelial cell monolayers: adhesion molecules and chemokines involved in subset-specific transmigration. J. Leukoc. Biol. 73:639–649.

32. Mantovani, A., T. Schioppa, S.K. Bows, F. Marchesi, P. Allavena, and A. Sica. 2003. Tumor-associated macrophages and dendritic cells as prototypic type II polarized myeloid populations. Tumour. 89:459–468.

33. Nakamura, K., I.R. Williams, and T.S. Kupper. 1995. Keratinocyte-derived monocyte chemoattractant protein 1 (MCP-1): analysis in a transgenic model demonstrates MCP-1 can recruit dendritic and Langerhans cells to skin. J. Invest. Dermatol. 105:635–643.

34. Niida, Y., A.O. Stemmer-Rachamimov, M. Logrip, D. Tapon, R. Perez, D.J. Kwiatkowski, K. Sims, M. MacCollin, D.N. Louis, and V. Ramesh. 2001. Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am. J. Hum. Genet. 69:493–503.

35. Fackler, I., J.E. DeClue, H. Rust, P.A. Vu, H. Kurtzer, A. Rutten, S. Kaddu, C.A. Sander, M. Volkenandt, M.W. Johnson, et al. 2003. Loss of expression of tuberin and hamartin in tuberous sclerosis complex-associated but not in sporadic angiomyofibromas. J. Cutan. Pathol. 30:174–177.

36. Wataya-Kaneda, M., Y. Kaneda, O. Hino, H. Adachi, Y. Hirayama, K. Seyama, T. Satoh, and K. Yoshikawa. 2001. Cells derived from tuberous sclerosis show a prolonged S phase of the cell cycle and increased apoptosis. Arch. Dermatol. Res. 293:460–469.

37. Darling, T.N., J. Wang, F. Takeuchi, T.C. Lei, S. Pack, Z. Zhuang, and J. Moss. 2002. Allelic deletion of the TSC2 gene in tuberous sclerosis skin tumors and cultured stromal cells. J. Invest. Dermatol. 119:215.

38. Takeuchi, F., J. Wang, J. Moss, and T. Darling. 2003. Hyperphosphorylation of p70S6K and ribosomal protein S6 in tuberous sclerosis skin tumors is inhibited by rapamycin. J. Invest. Dermatol. 121:A165.

39. Govindarajan, B., D.J. Brat, M. Cuiet, W.D. Martin, E. Murad, K. Litani, C. Cohen, F. Cermele, M. Nunnelle, B. Lefkow, et al. 2005. Transgenic expression of dominant negative tuberin through a strong constitutive promoter results in a tissue-specific tuberous sclerosis phenotype in the skin and brain. J. Biol. Chem. 280:5870–5874.

40. Castro, C.J., M.M. Campistol, D. Sancho, F. Sanchez-Madrid, E. Casals, and V. Andres. 2004. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1-independent pathway. Atherosclerosis. 172:31–38.

41. Oliveira, J.G., P. Xavier, S.M. Sampaio, C. Henriques, I. Tavares, A.A. Mendes, and M. Pestana. 2002. Compared to mycophenolate mofetil, rapamycin induces significant changes on growth factors and growth factor receptors in the early days post-kidney transplantation. Transplantation. 73:915–920.

42. Wasowska, B.A., X.X. Zheng, T.B. Strom, and J.W. Kupiec-Weglinski. 2001. Adjunctive rapamycin and CsA treatment inhibits monocyte/macrophage associated cytokines/chemokines in sensitized cardiac graft recipients. Transplantation. 71:1179–1183.

43. Harrington, L.S., G.M. Findlay, A. Gray, T. Tolkacheva, S. Wigfield, H. Rehbolz, J. Barnett, N.L. Reese, S. Cheng, P.R. Shepherd, et al. 2004. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166:213–223.

44. Shah, O.J., Z. Wang, and T. Hunter. 2004. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 deletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14:1650–1656.

45. Sartipy, P., and D.J. Loskutoff. 2003. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Natl. Acad. Sci. USA. 100: 7265–7270.

46. Kitamoto, S., and K. Egashira. 2003. Anti-macrophage chemoattractant protein-1 gene therapy for cardiovascular diseases. Expert. Rev. Cardiovasc. Ther. 1:393–400.

47. Gondillo, G.M., D. Onat, M. Stockinger, S. Roy, M. Atlay, F.M. Beck, and C.K. Sen. 2004. A key angiogenic role of monocyte chemoattractant protein-1 in hemangioendothelioma proliferation. Am. J. Physiol. Cell Physiol. 287:C866–C873.

48. Roach, E.S., M.R. Gomez, and H. Northrup. 1998. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J. Child Neurol. 13:624–628.

49. Soussek, T., R.S. Yeung, and M. Hengstschlager. 1998. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc. Natl. Acad. Sci. USA. 95:15653–15658.